30,974 Shares in CryoPort, Inc. $CYRX Acquired by White Pine Capital LLC

White Pine Capital LLC bought a new stake in shares of CryoPort, Inc. (NASDAQ:CYRX – Free Report) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 30,974 shares of the company’s stock, valued at approximately $539,000.

Other hedge funds have also recently made changes to their positions in the company. Wellington Management Group LLP bought a new position in CryoPort in the 2nd quarter worth about $8,398,000. Empire Financial Management Company LLC increased its stake in CryoPort by 24.4% during the 1st quarter. Empire Financial Management Company LLC now owns 502,575 shares of the company’s stock valued at $4,161,000 after purchasing an additional 98,714 shares in the last quarter. Royce & Associates LP bought a new stake in CryoPort during the 3rd quarter valued at about $7,073,000. Russell Investments Group Ltd. raised its holdings in CryoPort by 376.7% in the third quarter. Russell Investments Group Ltd. now owns 399,047 shares of the company’s stock worth $6,943,000 after buying an additional 315,343 shares during the last quarter. Finally, Squarepoint Ops LLC raised its holdings in CryoPort by 685.1% in the second quarter. Squarepoint Ops LLC now owns 368,424 shares of the company’s stock worth $5,784,000 after buying an additional 321,497 shares during the last quarter. 92.90% of the stock is owned by institutional investors.

Analysts Set New Price Targets

CYRX has been the topic of several analyst reports. Roth Capital reiterated a “buy” rating and issued a $21.00 target price on shares of CryoPort in a research note on Friday, August 7th. Piper Sandler raised shares of CryoPort to a “buy” rating in a research report on Tuesday, October 13th. BTIG Research raised their price target on shares of CryoPort from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, October 13th. KeyCorp boosted their price objective on shares of CryoPort from $17.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 6th. Finally, Robert W. Baird set a $26.00 price objective on CryoPort in a research report on Tuesday, October 13th. Seven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, CryoPort currently has a consensus rating of “Moderate Buy” and an average target price of $21.69.

View Our Latest Analysis on CryoPort

CryoPort Stock Performance

NASDAQ CYRX opened at $19.80 on Tuesday. CryoPort, Inc. has a one year low of $7.61 and a one year high of $21.78. The stock has a 50-day moving average of $17.51 and a 200 day moving average of $13.75. The company has a market capitalization of $1.00 billion, a price-to-earnings ratio of -20.41 and a beta of 1.89.

CryoPort (NASDAQ:CYRX – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07). The company had revenue of $50.22 million for the quarter, compared to the consensus estimate of $48.66 million. CryoPort had a negative net margin of 21.46% and a negative return on equity of 8.28%. On average, equities analysts predict that CryoPort, Inc. will post -0.88 earnings per share for the current fiscal year.

Insider Activity at CryoPort

In related news, insider Mark Sawicki sold 10,000 shares of the stock in a transaction that occurred on Tuesday, November 10th. The shares were sold at an average price of $19.93, for a total transaction of $199,300.00. Following the transaction, the insider owned 92,356 shares in the company, valued at $1,840,655.08. This represents a 9.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Daniel M. Hancock sold 74,379 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $20.21, for a total transaction of $1,503,199.59. Following the transaction, the director owned 69,052 shares in the company, valued at approximately $1,395,540.92. This trade represents a 51.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is owned by insiders.

CryoPort Company Profile

(Free Report)

Cryoport, Inc. provides temperature-controlled supply chain services for the life sciences industry. Its offerings support the development and commercial distribution of cell and gene therapies, biologics, reproductive medicine products and other temperature-sensitive materials. The company’s services include specialized shipping systems and packaging, transportation management, cryogenic storage, shipment monitoring and logistics support. These solutions are designed to help customers maintain required conditions and manage the handling of sensitive materials across clinical and commercial supply chains.

Featured Articles

Want to see what other hedge funds are holding CYRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CryoPort, Inc. (NASDAQ:CYRX – Free Report).

Institutional Ownership by Quarter for CryoPort (NASDAQ:CYRX)

Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.